Table 1 |
||||
|
Artificial oxygen carriers |
||||
|
Category |
Product |
Type |
MW (Daltons) |
Phase of testing |
|
|
||||
|
Perfluorocarbons |
Oxygent™ |
Perfluoroctylbromide |
450 to 500 |
Up to clinical phase III, discontinued |
|
Hemoglobin-based oxygen carrier |
HemAssist™ |
Diaspirin-crosslinked hemoglobin (human) |
65,000 |
Up to clinical phase III, discontinued |
|
Hemopure™ |
Polymerized bovine hemoglobin (bovine) |
250,000 |
Up to clinical phase III |
|
|
Polyheme™ |
Pyridoxylated glutaraldehyde-polymerized hemoglobin (human) |
150,000 |
Up to clinical phase III |
|
|
Hemospan™ |
Maleimide-activated polyethylene-glycol-modified hemoglobin (human) |
95,000 |
Up to clinical phase II, phase III planned |
|
|
Hemoglobin vesicles |
Oxygenix™ |
Hemoglobin containing liposomes (OXY-0301) |
Unpublished |
Experimental, up to phase I |
|
|
||||
|
Presented are the physiochemical characteristics and state of clinical research on artificial oxygen carrier. The manufacturers are as follows: Oxygent™, Alliance Pharmaceutical Corp., San Diego, CA, USA; HemAssist™, Baxter Healthcare, Round Lake, IL, USA; Hemopure™, Biopure Corp., Cambridge, MA, USA; Polyheme™, Northfield Lab Inc., Evanston, IL, USA; Hemospan™, Sangart Inc., San Diego, CA, USA; and Oxygenix™, Oxygenix Co. Ltd., Tokyo, Japan. |
||||
|
Angele et al. Critical Care 2008 12:218 doi:10.1186/cc6919 |
||||